EDITAS MEDICINE, INC. Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax
EDITAS MEDICINE, INC. (EDIT) had Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax of $76.00 thousand as of 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2018-03-08
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $76.00K.
- 2017-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $23.00K.
- 2017-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $68.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2017-12-31 | $76.00K 10-K · filed 2018-03-08 |
| 2017-09-30 | $23.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $68.00K 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |